- Belgrade '18
- Vienna '18
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
First Author: M.Gupta INDIA
Co Author(s): D. Gupta V. Vohra P. Malik
Back to previous
To assess the Vision related quality of life (VR-QOL) in Diabetic Macular Edema (DME) patients before and after treatment with Intravitreal Bevacizumab Injection.
Department of Ophthalmology, General Hospital Setting, National Capital Territory of Delhi, India
This study included 92 patients with DME. VR-QOL was assessed using the Interviewer administered format of the 25-item National Eye Institute Visual Functioning Questionnaire (NEI-VFQ-25) by the patients with DME before and 3 months after intravitreal bevacizumab injection. Clinical data were collected, including central macular thickness (CMT) using Optical Coherence Tomography (OCT) and best corrected visual acuity (BCVA) before and 3 months after intravitreal bevacizumab injection.
Significant improvement in the NEI-VFQ-25 sub scale scores was observed in patients with DME, 3 months after intravitreal bevacizumab injection. Subscale scores, including general vision, near activities, distance activities, social functioning, wellbeing, role difficulties and dependency improved after injection. However, subscale score regarding general health did not improve significantly. CMT and Visual acuity significantly improved 3 months after intravitreal bevacizumab injections. No bevacizumab-related systemic or ocular adverse effects following intravitreal drug injections were observed.
Intravitreal bevacizumab injection was found to be effective in treatment of DME as well as increase in vision related quality of life but not for general health. The research implications of the study indicate need for detailed evaluation of vision related quality of life and quality of life of patients with DME.